Ivan Kairatov is a distinguished biopharma expert whose career has been defined by a deep commitment to research, development, and technological innovation. With an intricate understanding of the drug development lifecycle, he has witnessed firsthand how targeted therapies can transform patient
The scientific community has long sought biological models that mirror the spontaneous and complex nature of human cancer without the need for artificial induction or genetic engineering in the laboratory environment. The lemon frost leopard gecko has emerged as a transformative subject in oncology
The pursuit of effective treatments for Duchenne muscular dystrophy has shifted focus toward managing cardiomyopathy, which currently stands as the most common cause of mortality for patients entering their second or third decade of life. Capricor Therapeutics recently faced significant headwinds
Mesothelioma has long remained one of the most difficult and aggressive cancers to treat within the modern medical landscape, primarily due to its ability to lie dormant for decades following asbestos exposure. By the time most patients receive a formal diagnosis, the disease has usually progressed
Recent breakthroughs in the field of molecular biology have unveiled a sophisticated biochemical mechanism that acts as a definitive binary toggle for malignant cellular proliferation, effectively governing the transition between dormant and aggressive tumor growth. For decades, oncologists
The intersection of computational intelligence and molecular biology has revealed a shocking source for the next generation of life-saving medicine: the same infectious proteins responsible for devastating neurological disorders like Creutzfeldt-Jakob disease. Researchers at the Perelman School of
